Kromek shares rise as Siemens deal drives return to profit

Kromek Group PLC shares climbed 5% after the detection technology company projected a return to first-half profit, primarily driven by an £8.2 million enablement agreement with Siemens Healthineers. This contract significantly boosted anticipated H1 revenue to at least £14.5 million, up from £3.7 million year-over-year, and shifted the group from a prior pre-tax loss of £5.7 million into profitability. The strong performance underpins management's confidence in achieving full-year revenue growth aligned with market expectations, with analysts like Cavendish maintaining a positive investment thesis and a 26p price target.

Analysis

Kromek Group PLC (AIM:KMK) shares rose 5% to 7.59p following a strong first-half trading update, projecting a return to profitability. This significant turnaround is primarily attributed to an £8.2 million "enablement agreement" with Siemens Healthineers, which boosted forecast H1 revenue to at least £14.5 million, a substantial increase from £3.7 million year-over-year. The company is moving into the black, contrasting sharply with last year's £5.7 million pre-tax loss and £2.3 million adjusted EBITDA loss.

Beyond the Siemens contract, underlying sales demonstrated robust growth, increasing approximately 70% to £6.3 million. Both the chemical, biological, radiological, and nuclear (CBRN) detection division and the advanced imaging arm contributed strong growth, indicating broad operational strength. This performance underpins management's confidence in achieving full-year revenue growth consistent with market expectations.

The positive momentum is echoed by analyst sentiment, with Cavendish maintaining its investment thesis and a 26p price target for KMK shares. This suggests a significant potential upside from the current trading price, reinforcing the market's optimistic outlook. The strong H1 results and positive guidance validate the company's strategic direction and operational execution.

Key Decisions for Investors

• Investors should monitor Kromek's full-year results to validate the projected revenue growth and sustained profitability, confirming the positive H1 momentum.
• Evaluate the long-term potential and scalability of the Siemens Healthineers contract, alongside the continued growth trajectory of the CBRN and advanced imaging divisions.
• Consider the substantial implied upside to the 26p analyst price target, assessing whether current market valuation fully reflects the company's return to profit and underlying growth.